AMINOREX
- Product Name
- AMINOREX
- CAS No.
- 2207-50-3
- Chemical Name
- AMINOREX
- Synonyms
- McN-742;Apiquel;AMINOREX;NSC 66592;CPDD 0039;NSC-66952;aminoxafen;aminoxaphen;Aminorex solution;AMINOREX USP/EP/BP
- CBNumber
- CB7107658
- Molecular Formula
- C9H10N2O
- Formula Weight
- 162.19
- MOL File
- 2207-50-3.mol
AMINOREX Property
- Melting point:
- 136-138°
- Boiling point:
- 288.88°C (rough estimate)
- Density
- 1.1436 (rough estimate)
- refractive index
- 1.5600 (estimate)
- Flash point:
- 2℃
- storage temp.
- -20°C
- solubility
- 0.1 M HCl: soluble
- form
- solid
- pka
- 8.19±0.70(Predicted)
- color
- white
Safety
- Hazard Codes
- T+,Xn,F
- Risk Statements
- 26/27/28-36-20/21/22-11
- Safety Statements
- 22-36/37/39-45-36/37-26-16
- RIDADR
- UN 2811 6.1/PG 2
- WGK Germany
- 3
- RTECS
- RQ4500000
- Hazardous Substances Data
- 2207-50-3(Hazardous Substances Data)
- DEA Controlled Substances
- CSCN: 1585
CSA SCH: Schedule I
NARC: No
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H225Highly Flammable liquid and vapour
H319Causes serious eye irritation
H331Toxic if inhaled
- Precautionary statements
-
P210Keep away from heat/sparks/open flames/hot surfaces. — No smoking.
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P311Call a POISON CENTER or doctor/physician.
N-Bromosuccinimide Price
- Product number
- A-1317
- Product name
- Aminorex-d5
- Packaging
- 5mg
- Price
- $1200
- Updated
- 2021/12/16
AMINOREX Chemical Properties,Usage,Production
Uses
It is a metabolite of Levamisole
Uses
Aminorex is a metabolite of Levamisole
Definition
ChEBI: Aminorex is a member of benzenes.
brand name
Apiquel (Ortho-McNeil);Mcn 742;Menocil.
World Health Organization (WHO)
Aminorex, an anorexic agent, was introduced over twenty years ago for the treatment of obesity. Between 1967 and 1971 its use was associated with cases of pulmonary hypertension which led to its withdrawal in the Federal Republic of Germany. WHO has no information to suggest that this drug remains commercially available.